Please login to the form below

Not currently logged in
Email:
Password:

TerSera Therapeutics

This page shows the latest TerSera Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Grünenthal buys Zomig rights as AZ slimming drive continues

Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

Latest news

  • AZ agrees to $320m deal for Zoladex AZ agrees to $320m deal for Zoladex

    TerSera Therapeutics acquires rights to oncology drug in US and Canada. ... AstraZeneca has sold the rights to its big-selling cancer drug Zoladex in Canada and the US to TerSera Therapeutics, as the UK firm moves to focus on its newer oncology

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...

Infographics